Last reviewed · How we verify
LI
LI is an immunotherapeutic agent designed to enhance immune response against cancer cells.
LI is an immunotherapeutic agent designed to enhance immune response against cancer cells. Used for Metastatic renal cell carcinoma.
At a glance
| Generic name | LI |
|---|---|
| Also known as | Multikine, Leukocyte interleukin, injection |
| Sponsor | CEL-SCI Corporation |
| Drug class | Cancer immunotherapy vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
LI (also known as Multikine) is a polyvalent therapeutic vaccine that combines multiple human cytokines to stimulate both innate and adaptive immune responses. It is intended to activate dendritic cells and promote T-cell mediated anti-tumor immunity, potentially enhancing the body's natural ability to recognize and eliminate cancer cells.
Approved indications
- Metastatic renal cell carcinoma
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Flu-like symptoms
Key clinical trials
- Clinical Genetics Branch Eligibility Screening Survey
- Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
- The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders (NA)
- An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer (PHASE2)
- Clinical and Genetic Studies of Li-Fraumeni Syndrome
- Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
- Improving Our Understanding of Respiratory Muscle Training to Facilitate Weaning From Mechanical Ventilation in the ICU (NA)
- Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |